Consequently, this insight offers a novel therapeutic strategy: inducing synthetic lethality by inhibiting Bcl-2 family members and YAP signaling, offering a potential avenue for overcoming drug resistance in highly metastatic GC, particularly in cases with NF2 and RASA1 deficiencies. The gene discussed is BCL2; the disease is gastric cancer.